Pear aims to redefine medicine by discovering, developing, and … PDTs are designed to directly treat disease, tested for safety and efficacy in randomized clinical trials, evaluated by the FDA, and prescribed by healthcare providers. PEARKO Therapeutics Inc. | 13 followers on LinkedIn. Dr. Maricich leads the Clinical/Regulatory/Quality and Medical Affairs group at Pear Therapeutics as the Chief Medical Officer and Head of Development. Pear Therapeutics. Prescription Digital Therapeutics, or PDTs, are software-based disease treatments. SECTOR SECTOR The leader in Prescription Digital Therapeutics | At Pear, our mission is clear: we are pioneers in Prescription Digital Therapeutics, or PDTs. Pear Therapeutics is a … | PEARKO Therapeutics Inc. is a biopharmaceutical company engaged in the practice of translational medicine working to drive the translation of molecular discoveries to patients. About Pear Therapeutics. Anesthesia Resident PGY4 - 2015-2019 Cardiothoracic Anesthesia Fellow at CCF 2019-2020 At Pear, our mission is clear: we are pioneers in PDTs. Greater Boston Area. © 2021 Pear Therapeutics, Inc. All Rights Reserved. We are primarily focused on novel and innovative therapies for cardiovascular diseases as these carry a … He leads and manages the development programs from Discovery/TPP stage, through Translational, Clinical Development, Regulatory submission and review as well as Medical Affairs. Multiple products, therapeutic areas, and development stages. Corey McCann. In his career, Alex has driven enterprise value from portfolio strategy through to commercial… The leader in Prescription Digital Therapeutics. Pear Therapeutics. Pear Therapeutics. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Advisory Board. PDTs are designed and tested much like traditional prescription drugs with one distinction: rather than swallowing a pill or taking an injection, patients are treated with software. He works to improve patient health and our healthcare system by investing in, advising, and providing leadership at innovative firms. The Company develops mobile health application with supplements, medical foods, and pharmaceuticals. Chief Medical Officer & Head of Development. Every day, we push the boundaries of technology to transform medicine. DevPro Biopharma is a Clinical Research and Development Accelerator with the mission to design, develop, and deliver molecules into medicine. Pear Therapeutics. He leads and manages the development programs from Discovery/TPP stage, through Translational, Clinical Development, Regulatory submission and review as well as Medical Affairs. The leader in Prescription Digital Therapeutics. Christopher Vo D.O., M.S. Chief Commercial Officer Pear Therapeutics. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Scientific Advisory Board. Previously Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and […] He founded a digital health firm while a med student that used AI and NLP to structure clinical data. See the complete profile on LinkedIn and discover David’s connections and jobs at similar companies. Pear’s third product, Somryst™ for the treatment of chronic insomnia, was the first product submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program and was authorized in March 2020. About Pear Therapeutics Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. COO Boston 200 State Street Boston, MA 02109 San Francisco 201 … In his career, Alex has driven enterprise value from portfolio strategy through to commercial… Boston. Chief Strategy Officer (CSO) Pear Therapeutics. Pear aims to redefine medicine by discovering, developing, and … Pear Therapeutics. In addition to overseeing subsequent pipeline… FORMER CONGRESSMAN (D-RI) AUTHOR, Mental Health … Scientific Director, Serious Mental Illness at Click Therapeutics, Inc. San Francisco Bay Area. Dr. Maricich leads the Clinical/Regulatory/Quality and Medical Affairs group at Pear Therapeutics as the Chief Medical Officer and Head of Development. Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital where he was involved with companies such as Cubist, PTC Therapeutics, Symyx and Syrrx. Content Marketing at Pear Therapeutics Boston, MA. President & CEO Cerulean Pharma, Inc. Mar 2015 – Jul 2017 2 years 5 months. Our Scientific Advisory Board includes leading experts from the fields of healthcare, pharmaceutical, and digital health. Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. Patrick Kennedy. Pear discovers, develops, and delivers clinically validated software to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Boston and San Francisco, November 23, 2020 – Pear Therapeutics, Inc. today announced that Corey McCann, M.D., Ph.D., President and CEO, will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1 at 12:10 p.m. Eastern Time. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. The leader in Prescription Digital Therapeutics | At Pear, our mission is clear: we are pioneers in Prescription Digital Therapeutics, or PDTs. Pear Therapeutics | 8,112 followers on LinkedIn. We are developing prescription digital therapeutics, or PDTs, to treat patients suffering from a range of serious diseases. Ronny Elor. Pear Therapeutics, Inc., (“Pear” or the “Company”) today announced that it has successfully closed an $80 million Series D financing led by … In addition to overseeing subsequent pipeline… Cerulean Pharma, Inc. 3 years. He leads and manages the development programs from Discovery/TPP stage, through Translational, Clinical Development, Regulatory submission and review as well as Medical Affairs. PEARKO Therapeutics Inc. is a biopharmaceutical company engaged in the practice of translational medicine working to drive the translation of molecular discoveries to patients. Our cross-functional team operates at the intersection of biology and software technology. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to. Innovative Therapies for Cardiovascular Disease. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Dr. Maricich completed his education and training at Harvard University, the University of Washington, the University of Notre Dame, and the University of Virginia. He has worked with and led successful teams and programs at Healthcare & Life Science/biotech (HLS) firms, including Corixa (acquired by GlaxoSmithKline), Xdynia (acquired by Cavion), Cavion (acquired by Jazz Pharmaceuticals), AWS, and Pear Therapeutics (1st FDA-cleared, clinically validated digital therapeutic to treat disease). LinkedIn. Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. © 2021 Pear Therapeutics, Inc. All Rights Reserved. Dr. Maricich leads the Clinical/Regulatory/Quality and Medical Affairs group at Pear Therapeutics as the Chief Medical Officer and Head of Development. Cambridge, MA. Pear aims to redefine medicine by discovering, developing, and … Prescription Digital Therapeutics for the treatment of Please be aware that Pear Therapeutics would never seek credit card information, checks, or other payment from job candidates for employment and be vigilant against fraudsters. Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. Pearl Therapeutics | 3,727 followers on LinkedIn. Dec 2017 – Present 2 years 11 months. Our cross-functional team operates at the intersection of biotechnology and software technology. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. About Pear Therapeutics. He leads and manages the development programs from Discovery/TPP stage, through Translational, Clinical Development, Regulatory submission and review as well as Medical Affairs. He has a proven record of building and leading business strategy and operations. ... Pear Therapeutics Jul 2017 - Sep 2019 2 years 3 months. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Our cross-functional team operates at the intersection of biology and software technology. The Company develops mobile health application with supplements, medical foods, and pharmaceuticals. serious disease, Pear Therapeutics Announces Publication of Economic Analysis Assessing the Cost-Effectiveness of reSET-O® in Treating Opioid Use Disorder (OUD). Pear Therapeutics | 8 501 abonnés sur LinkedIn. Pearl Therapeutics | 3.713 volgers op LinkedIn | Pearl Therapeutics, an AstraZeneca group company, was founded in 2006, with a mission to develop differentiated therapeutics for respiratory disease conditions prevalent worldwide, including chronic obstructive pulmonary disease (COPD). Every day, we push the boundaries of technology to transform medicine. Pear Therapeutics discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Dr. Maricich is a licensed, board-certified physician, investor, clinical developer and strategist. Andrew J. Schwab is a Founder and Managing Partner of 5AM Ventures. About Pear Therapeutics. 3 years 3 months. Pear Therapeutics Inc. provides software for healthcare services. Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. Pear’s second product, reSET-O® for the treatment of Opioid Use Disorder, was the first PDT to receive Breakthrough Designation and was authorized in December 2018. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to. Our pipeline is focused on product candidates across therapeutic areas to address unmet medical needs and demonstrate clinically relevant treatment effects. Dr. Maricich leads the Clinical/Regulatory/Quality and Medical Affairs group at Pear Therapeutics as the Chief Medical Officer and Head of Development. Apr 2019 – Present 1 year 7 months. In addition to overseeing subsequent pipeline programs across a broad-spectrum of disease areas (such as CNS/neuroscience, cardiovascular, and oncology), he led reSET (1st prescription digital therapeutic) and reSET-O (1st combination drug and software treatment) programs. Pear’s lead product, reSET®, for the treatment of Substance Use Disorder, and was the first PDT to receive authorization from FDA to improve disease outcomes. At Pear, our mission is clear: we are pioneers in PDTs. Pear Therapeutics Inc. provides software for healthcare services. He has a proven record of building and leading business strategy and operations. Pear aims to redefine medicine by discovering, developing, and …